Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13820096 | 0.91 | IRAK4 (0.60) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL10078156 | 0.84 | IRAK4 (0.56) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2139231 | 0.81 | IRAK4 (0.66) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2141251 | 0.80 | IRAK4 (0.71) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2138888 | 0.80 | IRAK4 (0.74) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2140620 | 0.80 | IRAK4 (0.67) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2139408 | 0.80 | IRAK4 (0.67) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2140489 | 0.79 | NPC1 (0.77) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL13818547 | 0.79 | NPC1 (0.68) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2137688 | 0.78 | NPC1 (0.64) | IRAK4NPC1RAB9AMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | claimed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | claimed |
| EP-2231652-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-29 | — | — | EP | claimed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | claimed |
| WO-2009074246-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | claimed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | claimed |
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| EP-2231652-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009074246-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CNR2, CYP11B2, CYP2C19 | IRAK4 788/4885NPC1 182/4885RAB9A 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.